Format

Send to

Choose Destination
Nat Med. 2006 Feb;12(2):190-7. Epub 2006 Feb 5.

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.

Author information

1
Istituto di Ricerche di Biologia Molecolare P. Angeletti, via Pontina km30,600, 00040 Pomezia, Rome, Italy.

Abstract

Three percent of the world's population is chronically infected with the hepatitis C virus (HCV) and at risk of developing liver cancer. Effective cellular immune responses are deemed essential for spontaneous resolution of acute hepatitis C and long-term protection. Here we describe a new T-cell HCV genetic vaccine capable of protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus. Suppression of acute viremia in vaccinated chimpanzees occurred as a result of massive expansion of peripheral and intrahepatic HCV-specific CD8(+) T lymphocytes that cross-reacted with vaccine and virus epitopes. These findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV or malaria, which can evade humoral responses.

PMID:
16462801
DOI:
10.1038/nm1353
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center